Home / Business and Economy / DexCom Stock: Big Moves, But Is It a Buy?
DexCom Stock: Big Moves, But Is It a Buy?
6 Jun
Summary
- DexCom is a $28B medical device firm specializing in diabetes monitoring.
- Stock declined 19.3% from its 52-week high but shows bullish momentum.
- Analysts maintain a 'Strong Buy' consensus with a target price suggesting upside.
San Diego-based DexCom, Inc. (DXCM) is a significant player in the medical device industry, with a market capitalization of $28 billion. The company designs, develops, and commercializes continuous glucose monitoring (CGM) systems crucial for diabetes management.
DXCM stock has experienced a notable decline, falling 19.3% from its 52-week high of $89.98, reached on July 30, 2025. Over the past three months, the stock has marginally decreased and underperformed the Dow Jones Industrial Average. A longer-term view reveals a 15.2% decline over the past 52 weeks, while the Dow Jones gained 21.5%.
Despite recent market performance, DXCM has been trading above its 200-day and 50-day moving averages since last month, suggesting a positive trend. The company reported strong Q1 2026 earnings on April 30, 2026, with revenue of $1.2 billion surpassing estimates. Adjusted EPS also exceeded forecasts at $0.56. DexCom anticipates full-year revenue between $5.16 billion and $5.25 billion.
Analysts maintain a highly optimistic outlook on DXCM, with a consensus rating of "Strong Buy" among 27 covering the stock. The mean price target of $81.58 indicates an expected 12.4% increase from current levels.
